BIOVIE INC. Research And Development Expense

• BIOVIE INC. showed a decrease of -59.9% in Research And Development Expense from 2024 to 2025.
• This data is from BIOVIE INC.'s annual report (Form 10-K), filed with the SEC on August 15, 2025.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2013: $19.2 thousand | Q1 2014: $19.4 thousand | Q3 2014: $3.4 thousand | Q3 2015: $0.00 | Q3 2016: $127.3 thousand | Q4 2016: $128.6 thousand | Q1 2017: $120.0 thousand | Q3 2017: $41.9 thousand | Q4 2017: $186.8 thousand | Q1 2018: $46.4 thousand | Q3 2018: $194.5 thousand | Q4 2018: $206.0 thousand | Q1 2019: $331.8 thousand | Q3 2019: $341.5 thousand | Q4 2019: $346.5 thousand | Q1 2020: $353.2 thousand | Q3 2020: $100.9 thousand | Q4 2020: $938.1 thousand | Q1 2021: $789.6 thousand | Q3 2021: $3.09 million | Q4 2021: $4.71 million | Q1 2022: $3.58 million | Q3 2022: $6.77 million | Q4 2022: $7.03 million | Q1 2023: $11.20 million | Q3 2023: $8.88 million | Q4 2023: $6.47 million | Q1 2024: $5.70 million | Q3 2024: $1.99 million | Q4 2024: $4.70 million | Q1 2025: $1.34 million | Q3 2025: $2.94 million | Q4 2025: $4.27 million.
• Over the full 12 years of available data (2014 to 2025), BIOVIE INC.'s Research And Development Expense has grown by 18,651.4%.
• Historical annual values: Fiscal year 2025: $9.27 million | Fiscal year 2024: $23.10 million | Fiscal year 2023: $33.30 million | Fiscal year 2022: $17.26 million | Fiscal year 2021: $2.54 million | Fiscal year 2020: $1.15 million | Fiscal year 2019: $1.01 million | Fiscal year 2018: $370.9 thousand | Fiscal year 2017: $466.4 thousand | Fiscal year 2016: $37.9 thousand | Fiscal year 2015: $4.2 thousand | Fiscal year 2014: $49.4 thousand.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026